scholarly journals Neither the maximum tumor size nor solid component size is prognostic in part-solid lung cancer: to be ground-glass opacity or not to be, is that really the question?

2016 ◽  
Vol 8 (9) ◽  
pp. 2334-2336 ◽  
Author(s):  
Kimihiro Shimizu ◽  
Yoichi Ohtaki ◽  
Seshiru Nakazawa ◽  
Akira Mogi ◽  
Hiroyuki Kuwano
Keyword(s):  
Lung Cancer ◽  
Tumor Size ◽  
Ground Glass Opacity ◽  
Solid Component ◽  
Ground Glass ◽  
Component Size

Evaluation of solid portions in non-small cell lung cancer—the solid part is not always measurable for clinical T factor

2020 ◽  
Vol 51 (1) ◽  
pp. 114-119
Author(s):  
Mariko Fukui ◽  
Kazuya Takamochi ◽  
Takehiro Ouchi ◽  
Yutaro Koike ◽  
Takashi Yaguchi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumour Size ◽  
Clinical Stage ◽  
Ground Glass Opacity ◽  
Solid Tumours ◽  
Solid Component ◽  
Imaging Features ◽  
Solid Portion ◽  
Component Size

Abstract Background Solid component size on thin-section computed tomography is used for T-staging according to the eighth edition of the Tumor Node Metastasis classification of lung cancer. However, the feasibility of using the solid component to measure clinical T-factor remains controversial. Methods We evaluated the feasibility of measuring the solid component in 859 tumours, which were suspected cases of primary lung cancers, requiring surgical resection regardless of the procedure or clinical stage. After excluding 126 pure ground-glass opacity tumours and 450 solid tumours, 283 part-solid tumours were analysed to determine the frequency of cases where the measurement of the solid portion was difficult along with the associated cause. Pathological invasiveness was also evaluated. Results The solid portion of 10 lesions in 283 part-solid nodules was difficult to measure due to an underlying lung disease (emphysema and pneumonitis). The solid portion of 62 lesions (21.9%) without emphysema and pneumonitis was difficult to measure due to imaging features of the tumours. Among the 62 patients, five had no malignancy and one with a tumour size of 33 mm had nodal metastasis. There were 56 lesions with a tumour size of ≤30 mm, wherein nodal metastases, vascular and/or lymphatic invasions were not observed. Conclusion For one-fifth of the part-solid tumours, measurement of the solid component was difficult. Moreover, these lesions had low invasiveness, especially in T1. The measurement of the solid portion and the classification of T1 in 1-cm increments may be complex.

scholarly journals Clinical Features of Ground Glass Opacity–Dominant Lung Cancer Exceeding 3.0 cm in the Whole Tumor Size

2018 ◽  
Vol 105 (5) ◽  
pp. 1499-1506 ◽  
Author(s):  
Shigeki Suzuki ◽  
Hiroyuki Sakurai ◽  
Masaya Yotsukura ◽  
Kyohei Masai ◽  
Keisuke Asakura ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Features ◽  
Tumor Size ◽  
Ground Glass Opacity ◽  
Ground Glass

scholarly journals Radiopathologic correlation of collision lung cancer with ground-glass opacity

2018 ◽  
Vol 27 (1) ◽  
pp. 45-48
Author(s):  
Shinsuke Uchida ◽  
Koji Tsuta ◽  
Masahiko Kusumoto ◽  
Kouya Shiraishi ◽  
Takashi Kohno ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Ground Glass Opacity ◽  
Ground Glass ◽  
Adenocarcinoma In Situ ◽  
Invasive Adenocarcinoma ◽  
Ki 67 ◽  
Lung Cancers ◽  
Collision Tumors ◽  
Minimally Invasive Adenocarcinoma ◽  
Epidermal Growth

Pulmonary collision tumors have been described as a special entity of synchronous multiple lung cancer. There have been no reports detailing the chronological changes in primary collision lung cancers on chest computed tomography. We report a case of ground-glass lung nodules gradually colliding with each other. The collision tumors of the lung were composed of minimally invasive adenocarcinoma and adenocarcinoma in situ with epidermal growth factor mutations. Immunohistochemically, the Ki-67 labeling indices were different in the 2 components. Ki-67 staining was useful to distinguish the 2 components. The 2 dominant ground-glass tumors grew slowly with radiologic and pathologic heterogeneity.

scholarly journals Identification of High-Risk of Recurrence in Clinical Stage I Non-Small Cell Lung Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Yasuhiro Tsutani ◽  
Yoshihisa Shimada ◽  
Hiroyuki Ito ◽  
Yoshihiro Miyata ◽  
Norihiko Ikeda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Clinical Stage ◽  
Small Cell ◽  
Stage I ◽  
Solid Component ◽  
Small Cell Lung ◽  
Risk Of Recurrence ◽  
Component Size ◽  
Solid Type

ObjectiveThis study aimed to identify patients at a high risk of recurrence using preoperative high-resolution computed tomography (HRCT) in clinical stage I non-small cell lung cancer (NSCLC).MethodsA total of 567 patients who underwent screening and 1,216 who underwent external validation for clinical stage I NSCLC underwent lobectomy or segmentectomy. Staging was used on the basis of the 8th edition of the tumor–node–metastasis classification. Recurrence-free survival (RFS) was estimated using the Kaplan–Meier method, and the multivariable Cox proportional hazards model was used to identify independent prognostic factors for RFS.ResultsA multivariable Cox analysis identified solid component size (hazard ratio [HR], 1.66; 95% confidence interval [CI] 1.30–2.12; P < 0.001) and pure solid type (HR, 1.82; 95% CI 1.11–2.96; P = 0.017) on HRCT findings as independent prognostic factors for RFS. When patients were divided into high-risk (n = 331; solid component size of >2 cm or pure solid type) and low-risk (n = 236; solid component size of ≤2 cm and part solid type) groups, there was a significant difference in RFS (HR, 5.33; 95% CI 3.09–9.19; 5-year RFS, 69.8% vs. 92.9%, respectively; P < 0.001). This was confirmed in the validation set (HR, 5.32; 95% CI 3.61–7.85; 5-year RFS, 72.0% vs. 94.8%, respectively; P < 0.001).ConclusionsIn clinical stage I NSCLC, patients with a solid component size of >2 cm or pure solid type on HRCT were at a high risk of recurrence.

scholarly journals Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer

2020 ◽  
Vol Volume 11 ◽  
pp. 105-111
Author(s):  
Ichiro Nagata ◽  
Takashi Ogino ◽  
Takeshi Arimura ◽  
Takashi Yoshiura
Keyword(s):  
Lung Cancer ◽  
Clinical Outcomes ◽  
Proton Beam ◽  
Ground Glass Opacity ◽  
Proton Beam Therapy ◽  
Ground Glass
Sign in / Sign up

Export Citation Format

Share Document